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BSTRACT
 
Background
 
The need for repeated treatment of
restenosis of a treated vessel remains the main lim-
itation of percutaneous coronary revascularization.
Because sirolimus (rapamycin) inhibits the prolifera-
tion of lymphocytes and smooth-muscle cells, we
compared a sirolimus-eluting stent with a standard
uncoated stent in patients with angina pectoris.
 
Methods
 
We performed a randomized, double-blind
trial to compare the two types of stents for revascular-
ization of single, primary lesions in native coronary ar-
teries. The trial included 238 patients at 19 medical
centers. The primary end point was in-stent late lu-
minal loss (the difference between the minimal lumi-
nal diameter immediately after the procedure and
the diameter at six months). Secondary end points
included the percentage of in-stent stenosis of the
luminal diameter and the rate of restenosis (luminal
narrowing of 50 percent or more). We also analyzed
a composite clinical end point consisting of death,
myocardial infarction, and percutaneous or surgical
revascularization at 1, 6, and 12 months.
 
Results
 
At six months, the degree of neointimal
proliferation, manifested as the mean (±SD) late lu-
minal loss, was significantly lower in the sirolimus-
stent group (¡0.01±0.33 mm) than in the standard-
stent group (0.80±0.53 mm, P<0.001). None of the
patients in the sirolimus-stent group, as compared
with 26.6 percent of those in the standard-stent group,
had restenosis of 50 percent or more of the luminal di-
ameter (P<0.001). There were no episodes of stent
thrombosis. During a follow-up period of up to one
year, the overall rate of major cardiac events was 5.8
percent in the sirolimus-stent group and 28.8 percent
in the standard-stent group (P<0.001). The difference
was due entirely to a higher rate of revascularization
of the target vessel in the standard-stent group.
 
Conclusions
 
As compared with a standard coronary
stent, a sirolimus-eluting stent shows considerable
promise for the prevention of neointimal proliferation,
restenosis, and associated clinical events. (N Engl J
Med 2002;346:1773-80.)
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HE growing use of stents has improved
the results of percutaneous coronary revas-
cularization.
 
1-5
 
 However, in-stent restenosis
continues to limit the long-term success of
this approach.
 
6,7
 
 For example, in a recent randomized
comparison of coronary-artery bypass surgery and
stenting in patients with multivessel disease, addition-
al revascularization procedures were performed with-
in one year in 21.0 percent of patients who had un-
dergone stenting, as compared with 3.8 percent of
patients treated surgically.
 
8
 
In controlled trials, several pharmaceutical agents
have failed to inhibit restenosis after coronary inter-
ventions.
 
9
 
 In contrast, the systemic and local delivery
of sirolimus (rapamycin), a macrocyclic lactone that
inhibits cytokine-mediated and growth-factor–medi-
ated proliferation of lymphocytes and smooth-muscle
cells, reduced neointimal proliferation in studies in
animals and in a small clinical study.
 
10-12
 
 We conduct-
ed a study to compare the performance of a coronary
stent that slowly releases sirolimus over a period of 30
days with that of a standard uncoated stent.
 
METHODS
 
Selection of Patients
 
The study was a randomized, double-blind trial performed at
19 medical centers (listed in the Appendix). It was approved by
T
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the ethics committee at each participating institution, and all pa-
tients gave written informed consent. The study was conducted
from August 2000 to August 2001.
Patients were eligible for the study if they were 18 to 85 years
old, were not pregnant and were protected against pregnancy
during the study, and had received a diagnosis of stable or unstable
angina or silent ischemia. Additional eligibility criteria were the
presence of a single primary target lesion in a native coronary artery
that was 2.5 to 3.5 mm in diameter and that could be covered by
an 18-mm stent; stenosis of 51 to 99 percent of the luminal diam-
eter, as estimated visually; and a flow rate of grade 1 or higher ac-
cording to the classification of the Thrombolysis in Myocardial In-
farction (TIMI) trial. Patients were not eligible for enrollment if
they had an evolving myocardial infarction, stenosis of the left-
main coronary artery, unprotected by a graft, that caused luminal
narrowing of 50 percent or more, an ostial lesion, a calcified le-
sion that could not be completely dilated before stenting, an an-
giographically visible thrombus within the target lesion, a left
ventricular ejection fraction of less than 30 percent, or an intol-
erance of aspirin, clopidogrel, ticlopidine, heparin, stainless steel,
or contrast material.
 
The Sirolimus-Eluting Stent
 
Sirolimus was blended in a mixture of nonerodable polymers,
and a layer of sirolimus–polymer matrix with a thickness of 5 µm
was applied to the surface of a stainless-steel, balloon-expandable
stent (Bx Velocity, Cordis, Johnson & Johnson). The stent was
loaded with a fixed amount of sirolimus per unit of metal surface
area (140 µg of sirolimus per square centimeter). A layer of drug-
free polymer was applied on top of the drug–polymer matrix as
a diffusion barrier to prolong the release of the drug. The stent
was designed to release approximately 80 percent of the drug
within 30 days after implantation.
 
Study Procedures
 
Codes for random assignments to the treatment groups were
generated by computer in blocks of four and were distributed in
sealed envelopes to each participating center. Patients were ran-
domly assigned to the groups in a 1:1 ratio.
Lesions were treated with the use of standard interventional
techniques. Stenting without predilation was prohibited. After suc-
cessful predilation, patients were randomly assigned in a double-
blind fashion to receive a standard uncoated stent or a sirolimus-elut-
ing stent mounted on a rapid-exchange delivery system and inflated
to 10 to 16 atm. The sirolimus-eluting stents were indistinguishable,
except under a microscope, from the uncoated stents. After the stent
had been implanted, further dilation was performed as necessary to
ensure that there was less than 20 percent residual stenosis, with a
TIMI grade III flow rate. In case of dissection or incomplete cover-
age of the lesion, additional stents of the same type as the assigned
stent (coated or uncoated) were used.
Intravenous boluses of heparin were administered to maintain an
activated clotting time that exceeded 250 seconds during the pro-
cedure and were discontinued within 12 hours. Treatment with as-
pirin, at a dose of at least 100 mg per day, was begun 12 hours be-
fore the procedure and continued indefinitely. A loading dose of
300 mg of clopidogrel was administered 48 hours before the pro-
cedure, followed by 75 mg daily for eight weeks. Alternatively, treat-
ment with ticlopidine, at a dose of 250 mg twice daily, was begun
one day before the procedure and continued for eight weeks. A suc-
cessful procedure was defined as the successful implantation of the
study device, with stenosis of less than 20 percent of the vessel di-
ameter and no major cardiac events during the hospital stay.
 
Follow-up
 
Patients were evaluated at 30 days and at 6 and 12 months.
They were asked specific questions about the interim develop-
ment of angina, according to the Canadian Cardiovascular Society
classification of stable angina
 
13
 
 and the Braunwald classification of
unstable angina.
 
14
 
 The patients were also monitored for major car-
diac events and for the need for additional revascularization of the
index target lesion. An electrocardiogram was obtained at each visit,
and an angiographic study was performed at a mean (±SD) of
180±30 days. Other studies and tests were performed at the discre-
tion of the investigators at the participating centers. Because of the
double-blind nature of the study, the decision to perform further
revascularization of the target lesion or vessel after the six-month
angiographic study was also left to the investigators’ discretion.
 
Quantitative Coronary Angiographic Evaluation
 
Coronary angiograms were obtained in multiple views after the
intracoronary injection of nitrates. Quantitative analyses of all an-
giographic data before, during, and after the procedure were per-
formed by an independent core laboratory (Cardialysis, Rotter-
dam, the Netherlands) with the use of edge-detection techniques.
The luminal diameter of the coronary artery and the degree of
stenosis were measured before dilation, at the end of the proce-
dure, and at six months. Restenosis was defined as stenosis of 50
percent or more of the luminal diameter. Late luminal loss was de-
fined as the difference between the minimal luminal diameter im-
mediately after the procedure and the diameter at six months. The
target lesion was defined as the stented segment plus the 5-mm
segments proximal and distal to the stented segment.
 
Intravascular Ultrasound Substudy
 
At the six-month visit, intravascular ultrasound examinations
were performed by six centers in subgroups of 48 patients who
had received a sirolimus-eluting stent and 47 who had received
an uncoated stent.
 
Study End Points
 
The primary angiographic end point was in-stent luminal late loss,
as determined by quantitative angiography. Secondary end points in-
cluded the percentage of in-stent stenosis of the luminal diameter,
the rate of restenosis (luminal narrowing of 50 percent or more),
and the minimal luminal diameter of the stented segment and of the
5-mm segments proximal and distal to the stent at six months.
The primary clinical end point of the study was a composite of
major cardiac events, including death, Q-wave or non–Q-wave
myocardial infarction, coronary-artery bypass grafting, and revas-
cularization of the target lesion or vessel 30 days, 6 months, and
12 months after the index procedure. A non–Q-wave myocardial
infarction was defined by an increase in the creatine kinase level
to more than twice the upper limit of the normal range, accom-
panied by an increased level of creatine kinase MB, in the absence
of new Q waves on the surface electrocardiogram.
The end points were adjudicated by an independent clinical-
events committee. In addition, a data and safety monitoring board
that was not affiliated with the study sponsor reviewed the data to
identify any safety issues related to the conduct of the study.
 
Statistical Analysis
 
We calculated that with a sample of 207 patients, the study
would have 90 percent power to detect a difference in the mean
late luminal loss of 0.25 mm between the two groups, assuming
a standard deviation of 0.55 mm in each group, with the use of
a two-group t-test and a two-sided significance level of 0.05.
All analyses were based on the intention-to-treat principle. For
continuous variables, differences between the treatment groups
were evaluated by analysis of variance or Wilcoxon’s rank-sum test.
For discrete variables, differences were expressed as counts and
percentages and were analyzed with Fisher’s exact test.
Revascularization of the target lesion or vessel and the compos-
ite of major adverse events during follow-up were analyzed by the
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Kaplan–Meier method. Differences between the event-free surviv-
al curves for the two groups were compared with the use of the
Wilcoxon and log-rank tests.
All listed authors participated in the study design, enrollment
of patients, and data interpretation. The data were held by the core
laboratory (Cardialysis, Rotterdam, the Netherlands), but all inves-
tigators had full access to them.
 
RESULTS
 
Characteristics of the Patients
 
Between August 2000 and January 2001, 120 pa-
tients were randomly assigned to receive the sirolimus-
eluting stent, and 118 were assigned to receive the
standard stent. With the exception of a significantly
higher percentage of men in the standard-stent group,
the two groups were similar with respect to all vari-
ables examined (Table 1). Overall, 76 percent of the
patients were men, and the mean age was 60.7 years,
with the expected prevalences of dyslipidemia, dia-
betes, hypertension, and current tobacco use. Stent-
ing was performed because of unstable angina in 50
percent of the patients. The target vessel was the left
anterior descending coronary artery in 50 percent of
the patients, the right coronary vessel in 27 percent,
and the left circumflex artery in 23 percent. Nearly
all the treated lesions were class B1 or B2 according
to the American College of Cardiology–American
Heart Association classification. Although all the tar-
get index lesions were primary lesions, 1.7 percent of
the patients had undergone previous coronary-artery
surgery and 18.1 percent had undergone previous
percutaneous interventions for the treatment of oth-
er lesions.
 
Procedural Characteristics
 
The lesions in the two groups were treated simi-
larly with the use of conventional techniques. Platelet
glycoprotein IIb/IIIa inhibitors, the use of which was
left to the discretion of the investigators at the partic-
ipating centers, were administered to 10.1 percent of
the patients in the sirolimus-stent group and 9.5 per-
cent of those in the standard-stent group. The two
groups did not differ significantly with respect to the
 
*Plus–minus values are means ±SD. There were no significant differences between the treatment
groups except for male sex (P=0.05).
†Unstable angina was defined according to the Braunwald classification,
 
14
 
 and stable angina accord-
ing to the classification of the Canadian Cardiovascular Society.
 
13
 
‡LAD denotes left anterior descending coronary artery, RCA right coronary artery, and LCX left
circumflex artery.
§The classification of the American College of Cardiology–American Heart Association was used.
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ATIENTS
 
(N=238)
S
 
IROLIMUS
 
 S
 
TENT
 
(N=120)
S
 
TANDARD
 
 S
 
TENT
 
(N=118)
 
Age (yr) 60.7±10.4 61.8±10.7 59.7±10.1
Male sex (%) 76 70 81
Previous myocardial infarction (%) 36 38 34
Diabetes mellitus (%) 19 16 21
Treated hypercholesterolemia (%) 40 38 43
Treated hypertension (%) 61 62 61
Current smoker (%) 30 27 33
Angina pectoris (%)†
Unstable
Stable
50
39
48
41
52
37
Silent ischemia (%) 11 11 11
Target coronary artery (%)‡
LAD
RCA
LCX
50
27
23
49
27
24
51
27
22
Lesion type (%)§
A
B1
B2
6
37
57
8
38
54
4
35
61
Reference diameter of the vessel (mm) 2.62±0.53 2.60±0.54 2.64±0.52
Length of lesion (mm) 9.58±3.25 9.56±3.33 9.61±3.18
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rate of successful stent placement (96.6 percent in the
sirolimus-stent group and 93.1 percent in the stand-
ard-stent group).
 
Quantitative Angiographic Analysis
 
Angiographic data at six months were available for
211 of the 238 patients (88.7 percent). The mean
reference diameter of the target vessel and the mean
length of the lesion at base line were similar in the
two groups (Table 1). The mean minimal luminal di-
ameter of the stented segment and the length of the
lesion before and after the procedure, as well as the
reduction in stenosis immediately after the proce-
dure, were also similar in the two groups (Table 2).
At six months, however, the mean minimal luminal di-
ameter of the stented segment was significantly greater
in the sirolimus-stent group. The mean in-stent late
loss, percentage of stenosis, and percentage of pa-
tients with 50 percent or more stenosis were ¡0.01
mm, 14.7 percent, and 0 percent, respectively, in the
sirolimus-stent group, as compared with 0.80 mm,
36.7 percent, and 26.6 percent, respectively, in the
standard-stent group (P<0.001 for each comparison).
Figure 1 shows the cumulative frequency of stenosis
immediately after the index procedure and at six
months in each treatment group. Table 2 shows the
results of subsegmental quantitative angiographic
analyses. The late luminal loss at both the proximal
and the distal edges of the stent was significantly less
in the sirolimus-stent group than in the standard-
stent group (P<0.001 for both comparisons). There
was a small degree of restenosis at the edges of the
standard stent that was not present with the siroli-
mus-eluting stent.
In the subgroup of patients with diabetes, 19 pa-
tients received sirolimus-eluting stents, and 25 received
standard stents. The minimal luminal diameter before
and after stenting was similar in the two groups (0.99
mm in the sirolimus-stent group and 0.93 mm in the
standard-stent group before the procedure and 2.37
and 2.36 mm, respectively, afterward). However, at six
months, the minimal luminal diameter was markedly
larger in the sirolimus-stent group (2.29 mm, vs. 1.56
mm in the standard-stent group;P<0.001); conse-
quently, the late loss was smaller (0.07 mm in the
sirolimus-stent group vs. 0.82 mm in the standard-
stent group, P<0.001) and the restenosis rate was
lower (0 percent vs. 41.7 percent, P=0.002).
 
Intravascular Ultrasound Evaluation
 
At six months, intravascular ultrasound examina-
tion showed no significant differences between the
two groups with respect to the volume of the stent,
the volume of the overall vessel, or the volume of
the plaque behind the stent. However, the sirolimus-
stent group had significantly less neointimal hyper-
plasia than did the standard-stent group (2±5 vs.
37±28 mm
 
3
 
) and significantly less volume obstruc-
tion, defined as the ratio of the volume of hyperpla-
sia to the volume of the stent, multiplied by 100
(1±3 percent vs. 29±20 percent) (P<0.001 for both
comparisons). These findings are consistent with the
 
*Plus–minus values are means ±SD. 
†Late loss was defined as the difference between the minimal luminal diameter immediately after placement of the stent and the minimal luminal diameter
at six months. The data are for patients for whom both post-procedural and follow-up measurements of the minimal luminal diameter were available.
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SIROLIMUS
STENT
STANDARD
STENT
 
P 
 
VALUE
SIROLIMUS
STENT
STANDARD
STENT
 
P 
 
VALUE
SIROLIMUS
STENT
STANDARD
STENT
 
P 
 
VALUE
 
Mean diameter (mm)
Before procedure
After procedure
At 6 mo
2.66±0.59
2.78±0.55
2.73±0.59
2.62±0.58
2.78±0.53
2.55±0.60 <0.05
—
2.83±0.41
2.88±0.48
—
2.82±0.40
2.23±0.50 <0.001
2.33±0.55
2.45±0.47
2.50±0.53
2.41±0.58
2.50±0.52
2.43±0.52
Minimal luminal diameter (mm)
Before procedure
After procedure
At 6 mo
2.27±0.60
2.47±0.53
2.41±0.58
2.23±0.66
2.46±0.54
2.19±0.64 0.01
0.94±0.31
2.43±0.41
2.42±0.49
0.95±0.35
2.41±0.40
1.64±0.59 <0.001
1.97±0.54
2.13±0.47
2.20±0.51
2.07±0.59
2.21±0.51
2.12±0.51
Stenosis (% of luminal diameter)
Before procedure
After procedure
At 6 mo
15.2±9.1
11.4±5.0
12.2±4.7
16.2±12.2
12.1±5.2
15.4±8.4 <0.001
63.6±10.7
11.9±5.9
14.7±7.0
64.0±10.2
14.0±6.8
36.7±18.1
<0.05
<0.01
15.9±9.4
13.0±5.2
12.2±4.9
14.6±9.8
11.7±5.1
13.2±6.9
0.057
Late loss (mm)† 0.05±0.39 0.29±0.48 <0.001 ¡0.01±0.33 0.80±0.53 <0.001 ¡0.09±0.30 0.12±0.44 <0.001
»50% restenosis (% of patients) 0 0 0 26.6 <0.001 0 0
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nearly complete suppression of in-stent neointimal
hyperplasia by sirolimus. In addition, there was no
evidence of an “edge effect,” aneurysm formation, in-
stent thrombosis, or persistent dissection.
Adverse Events
Major cardiac events are listed in Table 3. Three
patients in each group had a myocardial infarction at
the time of stenting. In the sirolimus-stent group, two
of the patients with myocardial infarction underwent
angiography in the hospital, which showed a patent
stent in each. The third patient had a non–Q-wave
myocardial infarction, and the angiographic study per-
formed at six months showed a patent stent. One re-
cipient of a standard stent underwent further percu-
taneous revascularization of the target vessel for the
treatment of a lesion other than the index lesion.
During a follow-up period of up to one year, two
patients in the standard-stent group (1.7 percent)
died: one had a myocardial infarction and died sud-
denly several weeks later, and the other had a gastric
hemorrhage. Two patients in the sirolimus-stent group
(1.7 percent) also died: one had a subarachnoid hem-
orrhage, and the other had gastrointestinal cancer.
One patient in each group underwent surgical revas-
cularization of the index target vessel.
Percutaneous revascularization of the target lesion
was performed in 27 recipients of standard stents (22.9
percent) but in none of the recipients of sirolimus-elut-
ing stents (P=0.001). Subacute or late thrombotic oc-
clusion of the stent did not occur in either group.
Kaplan–Meier estimates of event-free survival are
shown in Figure 2. The overall rate of major cardiac
events was 5.8 percent in the sirolimus-stent group
and 28.8 percent in the standard-stent group
(P<0.001). The difference between the two groups
was entirely due to the greater need for repeated re-
vascularization of the target vessel in the standard-
stent group. No adverse effects were attributable to
the sirolimus coating of stents.
DISCUSSION
We found that use of a sirolimus-eluting stent re-
sulted in the virtual elimination of in-stent neointimal
hyperplasia; thus, there was no angiographic evidence
of restenosis and no need for repeated interventions.
Since the introduction of angioplasty, restenosis has
been a major factor limiting the long-term success
of percutaneous coronary revascularization.15 The
refinement of stenting techniques in the past decade
has substantially improved the overall results of the
procedure.3,4,16,17 Despite considerable efforts to pre-
vent the development of restenosis, however, includ-
ing systemic or local delivery of biochemical substanc-
Figure 1. Cumulative Frequency of Stenosis Immediately after Stenting and at Six Months in Patients
Who Received Sirolimus-Eluting Stents and in Those Who Received Standard Stents.
The broken lines indicate the percentage of lesions with restenosis (above the line, 22.9 percent) and
without restenosis (below the line, 77.1 percent) according to the study definition.
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es and drugs9 and the use of various devices,18-22
additional target-vessel revascularization is required
in more than 15 percent of patients.8,23 Although
catheter-based brachytherapy is effective in the treat-
ment of in-stent restenosis,24 its value in the treatment
of primary lesions is less clear. Furthermore, the use
of brachytherapy is limited by its high cost and bur-
densome instrumentation and by the risks inherent
in the use of radioisotopes.
In this context, the benefit of the sirolimus-elut-
ing stent in our study was particularly striking. This
new device appears to have virtually eliminated the
development of neointimal proliferation. Yet its use
did not require special implantation techniques or
instrumentation and was innocuous within the time
frame of the study.
In the group of patients with sirolimus-eluting
stents, the percentage of stenosis at six months was
essentially the same as that immediately after the pro-
cedure and was in all cases less than 35 percent. The
virtual absence of late loss in the luminal diameter in
this group is consistent with the arrest of in-stent
neointimal proliferation by sirolimus. Also noteworthy
was the absence of restenosis and major cardiac events
in the patients with diabetes who received sirolimus-
eluting stents. Whether these effects can be sustained
for several years remains to be determined. The results
thus far suggest that the use of an appropriate ther-
apeutic agent when growth-factor–induced cell pro-
liferation is at its peak can have substantial effects on
the process of in-stent restenosis.
Sirolimus, a macrolide antifungal agent with a
*Both patients had had previous myocardial infarctions.
†Coronary-artery bypass grafting was performed to treat progressive dis-
ease of the left main coronary artery and the ostium of the anterior de-
scending coronary artery, not the target lesion.
‡P<0.001 for the comparison between the two groups with the use of
Fisher’s exact test.
§P<0.001 for the comparison between the two groups with the use of
the log-rank test.
TABLE 3. CARDIAC EVENTS IN THE HOSPITAL 
AND DURING ONE YEAR OF FOLLOW-UP.
EVENT
SIROLIMUS
STENT
(N=120)
STANDARD
STENT
(N=118)
Before discharge
Death — no.
Myocardial infarction — no.
Q-wave
Non–Q-wave
Coronary-artery bypass grafting — no.
0
3
2
1
0
0
3
1
2
0
After discharge
Death — no.
Myocardial infarction — no.
Q-wave
Non–Q-wave
Coronary-artery bypass grafting
Percutaneous revascularization 
of target lesion — no.
2
1
0
1
1†
0
2*
2
0
2
1
27
Total — no. (%) 7 (5.8) 34 (28.8)‡
Cumulative event-free survival — % 94.1 70.9§
Figure 2. Kaplan–Meier Estimates of Survival Free of Myocardial Infarction and Repeated Revascular-
ization among Patients Who Received Sirolimus-Eluting Stents and Those Who Received Standard
Stents.
The rate of event-free survival was significantly higher in the sirolimus-stent group than in the stand-
ard-stent group (P<0.001 by the Wilcoxon and log-rank tests).
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unique antiproliferative mode of action and power-
ful immunosuppressant properties, inhibits several
regulators of cell-cycle progression and the migra-
tion of vascular smooth-muscle cells.25 Yet studies in
animals have shown that reendothelialization may oc-
cur even while sirolimus is being eluted.26 Moreover,
recent experiments in animals have shown that siroli-
mus blocks inflammation.26 These antiproliferative,
antimigratory, and antiinflammatory properties are
responsible for the efficacy of sirolimus therapy in
preventing acute rejection of renal allografts and ar-
teriopathy of cardiac allografts, as well as in-stent re-
stenosis. The wide safety margin of sirolimus27 and
the minuscule amounts of drug released into the
blood explain the absence of detectable adverse ef-
fects in our trial and in a previous clinical study.12
The restenosis rate of 27 percent in the standard-
stent group may seem high. However, on the basis
of a linear regression model derived from the Stent
Restenosis Study and the Benestent I and II studies
(unpublished data), the predicted rate of restenosis
for our patient cohort was approximately 28 per-
cent. Of the 27 patients in the standard-stent group
who underwent revascularization of the target vessel
(22.9 percent), 16 did so because of angina or ab-
normal stress tests and 11 because of angiographic
evidence of restenosis.
Despite the absence of late luminal loss in the siroli-
mus-stent group, reendothelialization presumably oc-
curred, since none of the patients in the group had
acute, subacute, or late thrombosis, even though they
received combined antiplatelet therapy for only two
months. These findings are similar to reported ob-
servations in animals.26
We enrolled patients with single lesions that were
up to 18 mm long. Whether the positive results in
these patients can be expected in patients with more
complex or more extensive disease remains to be de-
termined. However, a subgroup analysis showed that
the results in patients with diabetes were similar to
those in patients without diabetes. 
In this trial, 2.5-mm stents were used in 18 percent
of the patients randomly assigned to the sirolimus-
stent group. Furthermore, division of the treatment
groups into thirds according to the vessel diameter re-
vealed virtually identical late luminal loss, even in the
smallest arteries.
Stents that deliver drugs are complex devices with
three components: the stent, the drug, and the coat-
ing. The long-term outcome of treatment with these
devices will depend on the response to all three com-
ponents.
In conclusion, patients with angina who received
sirolimus-eluting stents for the treatment of single,
primary lesions in native coronary arteries had no
angiographic evidence of late luminal loss or in-stent
restenosis at six months, no episodes of thrombosis,
and a very low rate of cardiac events at one year.
Supported by a grant from Cordis, a Johnson & Johnson company.
Dr. Falotico is an employee of Cordis.
We are indebted to Drs. Rodolphe Ruffy, Brian Firth, and Dennis
Donohoe for their assistance in drafting and reviewing the manuscript.
APPENDIX
The following investigators and institutions participated in the RAVEL
study: Steering Committee — M.C. Morice (chairperson), Massy, France;
P.W. Serruys (cochairperson), Rotterdam, the Netherlands; K. Nijssen,
Rotterdam, the Netherlands; C. Bode, Freiburg, Germany; P. Barragan,
Marseilles, France; and M. Delattre, Waterloo, Belgium; Sponsor — Cor-
dis, Johnson & Johnson, Warren, N.J., E. Wülfert (program coordinator)
and C. Demeyere, Waterloo, Belgium; Data and Safety Monitoring
Board — J.G.P. Tijssen, Amsterdam; G. Steg, Paris; and P. Vranckx, Rot-
terdam, the Netherlands; Data Management — Cardialysis, Rotterdam,
the Netherlands; Clinical Events Committee — J. Deckers (chairperson),
Rotterdam, the Netherlands; J.A.M. te Riele, Breda, the Netherlands; and
L.G.P.M. van Zeijl, Rotterdam, the Netherlands; Core Angiographic
Laboratory — C. Disco, K. Nijssen, and A. Spierings, Cardialysis, Rotter-
dam, the Netherlands; Clinical sites — M.C. Morice, T. Lefèvre, and Y.
Louvard, Institut Cardiovasculaire Paris Sud, Massy, France; P.W. Serruys,
M. van den Brand, D. Foley, W. van der Giessen, P. de Feyter, P. Smits, and
J. Vos, Thoraxcentrum, Rotterdam, the Netherlands; C. Bode, M. Rave,
and C. Holubarsch, Albert Ludwigs Universitätskliniken, Freiburg, Germa-
ny; P. Barragan, J.B. Simeoni, C.O. Roquebert, and P. Commeau, Clinique
Beauregard, Marseilles, France; G. Schuler, P. Sick, and M. Woinke, Herz-
zentrum, Leipzig, Germany; G.J. Laarman and F. Kiemeney, Onze Lieve
Vrouwe Gasthuis, Amsterdam; W. Wijns, B. de Bruyne, J. Bartunek, P. de
Bruyne, G.R. Heyndrickx, Onze Lieve Vrouwe Kliniek, Aalst, Belgium; J.
Fajadet, J. Marco, B. Farah, P. Sousa, and M. Boccalatte, Clinique Pasteur,
Toulouse, France; J.L. Guermonprez, Hôpital Européen Georges Pompid-
ou, Paris; A. Colombo, C. di Mario, R. Albiero, and N. Corvaja, Centro
Cuore Columbus, Milan, Italy; A. Bartorelli, S. Galli, F. Fabbiochi, P. Mo-
torsi, D. Trabattoni, and A. Loaldi, Centro Cardiologico Monzino, Milan,
Italy; G. Guagliumi, O. Valsecchi, M. Tespili, A. Vassileva, and A. Saimo,
Ospedali Riuniti di Bergamo, Bergamo, Italy; F. Molnàr, R.G. Kiss, L. Ma-
jor, and G. Bokori, Semmelweis Egyetem Egészégtudomanyi Kar, Budap-
est, Hungary; E. Ban Hayashi, I. Sanchez, J. Gaspar, R. Villavicencio, and
M.A. Pena Duque, Instituto Nacional de Cardiologia, Mexico City, Mex-
ico; J.E. Sousa, E. Sousa, A.S. Abizaid, A. Abizaid, A. Sousa, F. Feres, L.A.
Mattos, M. Costa, and R. Staico, Institute Dante Pazzanese de Cardiolo-
gia, São Paulo, Brazil; M. Perin, E. Ribeiro, E. Martinez, P. Soares, and F.
Demartino, University Hospital of São Paulo, São Paulo, Brazil; D. Blan-
chard and O. Bar, Clinique Saint-Gatien, Tours, France; A. Cribier, H.
Eltchaninoff, Centre Hospitalier Universitaire de Rouen, Rouen, France.
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CORRECTION
Sirolimus-Eluting Coronary Stents
To the Editor: The results of the RAVEL study (Randomized Study
with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in
the Treatment of Patients with de Novo Native Coronary Artery Le-
sions) (June 6 issue)1 are promising and bring to light the ethical and
financial dilemma that is likely to surface once drug-eluting stents are
approved for general use. The projected cost of each stent is likely
to be about $3,200. Of course, from a financial and societal stand-
point, it will not be possible to deploy drug-eluting stents in every case
of percutaneous coronary-stent intervention. From an individual pa-
tient’s standpoint, a drug-eluting stent may be a panacea for a given
treated lesion. How does one arrive at a balance? In what cases
should the use of a drug-eluting stent be considered absolutely jus-
tified and maybe even crucial? We need to arrive at guidelines to
determine the point at which the cost of the device offsets the need
for repeated coronary interventions, especially in situations in which
the risk of restenosis is high or in which presentation with resteno-
sis will probably result in coronary-artery bypass surgery. For exam-
ple, in patients with diabetes who have a long diseased segment in a
small-caliber, proximal left anterior descending artery, treatment with
a drug-eluting stent may make good sense. However, a focal lesion
in a large-caliber, distal right posterolateral branch in a nondiabetic,
nonsmoking patient may not justify the use of a drug-eluting stent.
Sanjiv Sharma, M.D.
Brijesh Bhambi, M.D.
William Nyitray, M.D.
Bakersfield Heart Hospital
Bakersfield, CA 93301
sanjiv1122@yahoo.com
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Dr. Morice replies:
To the Editor: Sharma and colleagues raise a crucial issue. The cost
of drug-eluting stents is indeed very high. However, this high initial
cost is expected to be significantly offset by the reduced rate of re-
current events and the subsequent reduced need for repeated inter-
vention observed in our study at one year among the recipients of
sirolimus-eluting stents. The cost-effectiveness analysis that was an
objective of the RAVEL trial should provide a clearer picture of the
financial aspects of the use of these new devices. As they are in-
creasingly used, the price of these stents is likely to decrease, as is
often the case with any new device.
In the meantime, the frustration felt by physicians and their patients
in view of the financial dilemma rightfully underlined by Sharma et al.
seems more than justified. Nevertheless, the spectacular therapeu-
tic progress brought about by the drug-eluting stents is a reality that
cannot be denied.
The following RAVEL investigators were inadvertently omitted in the
Appendix to our article: C.R. Costantini, M. de Freitas Santos, S.G.
Tarbine, D.A. Zanerttini, and J.L. Lazarte, Clínica Cardiológyca C.
Costantini, Curitiba Paraná, Brazil.
Marie-Claude Morice, M.D.
Institut Cardiovasculaire Paris Sud
91300 Massy, France
mc.morice@icps.com.fr
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